IL17A and rheumatoid arthritis: It is used in the immunotherapy of psoriasis or rheumatoid arthritis (RA).As a consequence, secukinumab inhibits proinflammatory cytokines release and reduces the role of IL-17 in causing the symptoms of the previously mentioned autoimmune diseases.